Business Context and Reporting Period
This Form 8-K is a current report filed by Matinas BioPharma Holdings, Inc. on November 27, 2024. The report discloses a corporate governance event that occurred on November 22, 2024, regarding the resignation of a member of the Board of Directors.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a personnel change and does not contain financial performance data.
Material Changes
The material change reported is the departure of Kathryn Penkus Corzo from the Board of Directors, effective immediately on November 22, 2024. In connection with this resignation, she also stepped down from the Compensation Committee and the Nominating and Corporate Governance Committee. The Company stated that the resignation was due to other professional obligations and was not the result of a material disagreement or change in the Company's direction.
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance, outlook, or management commentary regarding business operations. No new risks, contingencies, or unusual items were disclosed in this specific report.
Key Facts for Investors to Verify
- Confirmation of the Board's composition following the resignation of Kathryn Penkus Corzo.
- Whether the Company intends to appoint a replacement director to fill the vacancy.
- Verification that the resignation was not indicative of undisclosed internal disagreements.